PRESS RELEASE published on 10/31/2023 at 12:00, 2 years 1 month ago AmplifyBio and Vector BioMed Partner to Manufacture Plasmids and Share Capabilities that Enhance the Safety and Scalability of Lentiviral-based Gene Therapeutics
PRESS RELEASE published on 07/12/2023 at 13:00, 2 years 4 months ago AmplifyBio Completes Acquisition of Intellectual Property to Offer Non-Viral Gene Editing Services for Clients
PRESS RELEASE published on 05/25/2023 at 13:03, 2 years 6 months ago AmplifyBio Celebrates 2 Years of Innovative Solutions, Preclinical Drug Development and Safety
PRESS RELEASE published on 05/15/2023 at 13:00, 2 years 6 months ago AmplifyBio Adds Manufacturing Capabilities to Expand Service Portfolio
PRESS RELEASE published on 04/03/2023 at 13:00, 2 years 8 months ago Dispatch Media Group Names AmplifyBio a Winner of The Columbus Top Workplaces 2023 Award
PRESS RELEASE published on 03/16/2023 at 12:00, 2 years 8 months ago AmplifyBio Emerges as a Leader in Cell Therapy Characterization, Filling a Gap in Pre-Clinical Development
Published on 12/05/2025 at 02:35, 5 hours 31 minutes ago Future Fuels Initates Drill Permitting at Hornby; Marketing Update
Published on 12/05/2025 at 01:00, 7 hours 6 minutes ago BEACN Closes First Tranche of Non-Brokered Private Placement
Published on 12/04/2025 at 23:05, 9 hours 1 minute ago BlackBerry to Announce Third Quarter Fiscal Year 2026 Results on December 18, 2025
Published on 12/04/2025 at 23:00, 9 hours 6 minutes ago NXT Energy Solutions Completes Data Acquisition for SFD Survey
Published on 12/05/2025 at 07:00, 1 hour 6 minutes ago Swiss Re targets a net income of USD 4.5 billion in 2026; refreshed strategy to strengthen core business
Published on 12/05/2025 at 03:30, 4 hours 36 minutes ago CGTN: What makes cooperation between China and France a two-way success
Published on 12/04/2025 at 23:50, 8 hours 16 minutes ago EQS-Adhoc: Dexus Finance Pty Limited: Dexus prices A$500 million of subordinated notes
Published on 12/04/2025 at 20:25, 11 hours 41 minutes ago Newmark Appoints Globally Recognized Real Estate Executive Peter Trollope to Lead Occupier Solutions
Published on 12/04/2025 at 20:15, 11 hours 51 minutes ago Galimedix Therapeutics presents compelling Phase 1 study results showing excellent safety and pharmacokinetics with oral small molecule GAL-101 at CTAD 2025
Published on 12/04/2025 at 18:14, 13 hours 52 minutes ago Résiliation d'une convention conclue entre actionnaires
Published on 12/04/2025 at 18:00, 14 hours 6 minutes ago Informations relatives au nombre total de droits de vote et d’actions composant le capital social au 28 novembre 2025
Published on 12/04/2025 at 18:00, 14 hours 6 minutes ago Information concerning the total number of voting rights and shares in the share capital as of November 28, 2025
Published on 12/04/2025 at 17:45, 14 hours 21 minutes ago Informations relatives au nombre total de droits de vote et d’actions
Published on 12/04/2025 at 17:45, 14 hours 21 minutes ago MONTHLY INFORMATION RELATING TO THE TOTAL NUMBER OF VOTING RIGHTS AND SHARES MAKING UP THE SHARE CAPITAL
